Ex-FDA AI regulator says biopharma is over-reading the agency's guidance out of fear, not necessity

Tala Fakhouri, formerly a senior figure in FDA's AI regulatory work and now in industry, argues that biopharma companies are interpreting FDA's AI guidance more conservatively than the agency intended. She also acknowledges FDA could be doing more to reduce ambiguity and build industry confidence.

Why it matters

Tala Fakhouri's position is worth taking seriously precisely because she sat on the other side of the table. Her argument is not that FDA's guidance is good enough, but that companies are adding layers of caution the guidance never demanded. That is a meaningful distinction. Regulatory conservatism in pharma is often rational, but there is a point where it becomes a reflexive organizational habit that slows everything down without actually reducing risk.

The deeper issue here is that FDA guidance on AI is genuinely underdeveloped relative to how fast the technology is moving, and that gap creates anxiety that compliance teams fill with restriction. Fakhouri is right that the agency can do more. But her message to industry is also clear: stop using regulatory ambiguity as a blanket excuse. If you want to move faster on AI, start by understanding what the rules actually say, not what your most cautious lawyer thinks they imply.

What to watch

Whether FDA responds with clearer interpretive guidance or concrete examples that give companies actual handrails rather than principles they can argue about indefinitely.